Update on systemic vasculitides
| Autor: | Siddiq Anwar, M Yousuf Karim |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Consensus Complement Pathway Alternative Anti-Inflammatory Agents Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Antibodies Monoclonal Humanized Antibodies Antineutrophil Cytoplasmic Pathology and Forensic Medicine Biological Factors 03 medical and health sciences 0302 clinical medicine B-Cell Activating Factor medicine Humans 030212 general & internal medicine Precision Medicine Intensive care medicine Receptor Anaphylatoxin C5a Receptors Scavenger 030203 arthritis & rheumatology business.industry Systemic Vasculitis Autoantibody Immunoglobulins Intravenous Lysosome-Associated Membrane Glycoproteins General Medicine medicine.disease Immunoglobulin G Immunology Tumor Necrosis Factor Inhibitors Interleukin-5 Rituximab business Vasculitis Immunosuppressive Agents Systemic vasculitis |
| Zdroj: | Journal of Clinical Pathology. 70:476-482 |
| ISSN: | 1472-4146 0021-9746 |
| DOI: | 10.1136/jclinpath-2016-203875 |
| Popis: | Management of systemic vasculitis has been revolutionised over the last decade with the introduction of targeted biological agents. With an increase in both the prevalence and the recognition of vasculitis as well as the high cost of these agents, it is important to ensure their most optimal utilisation. The goals of vasculitis therapy include the induction and maintenance of remissions, preventing relapses, reducing the toxicity of therapy with the aim of reducing morbidity and mortality as well as improving the quality of life of those afflicted. This review focuses on the recent advances in the diagnosis, surveillance and treatment of these conditions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|